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Abstract
Background: The association of lichen planus with hepatitis C (HCV) has been widely reported
in the literature. However, there are wide geographical variations in the reported prevalence of
HCV infection in patients with lichen planus. This study was conducted to determine the frequency
of hepatitis C in Iranian patients with lichen planus at Razi hospital, Tehran.
Methods: During the years 1997 and 1998, 146 cases of lichen planus, 78 (53.1%) women and 69
(46.9%) men were diagnosed. They were diagnosed on the basis of the usual clinical features and,
if necessary, typical histological findings. The patients were screened for the presence of anti-HCV
antibodies by third generation ELISA and liver function tests. We used the results from screening
of blood donors for anti HCV (carried out by Iranian Blood Transfusion Organization) for
comparison as the control group.
Results: Anti-HCV antibodies were detected in seven cases (4.8%). This was significantly higher
than that of the blood donors' antibodies (p < 0.001). The odds ratio was 50.37(21.45–112.24). A
statistically significant association was demonstrated between erosive lichen planus and HCV
infection. Liver function tests were not significantly different between HCV infected and non-
infected patients.
Conclusion: HCV apears to have an etiologic role for lichen planus in Iranian patients. On the
other hand, liver function tests are not good screening means for HCV infection.
Background
Lichen planus (LP) is an idiopathic inflammatory disease
with characteristic clinical and pathologic features affect-
ing the skin, mucous membranes, nails, and hair. It is
likely that both endogenous-genetic and exogenous-envi-
ronmental components such as some drugs or some infec-
tion(s) may interact to elicit the disease [1]. An increased
prevalence of chronic liver diseases has been reported in
patients with LP, including primary biliary cirrhosis and
chronic active hepatitis or cirrhosis of unknown origin [2-
5]. Recently, a more widespread and chronic viral disease,
hepatitis C (HCV), has been implicated in triggering LP.
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While some studies of selected populations with LP have
confirmed a significant association with HCV [3,6-9],
other investigations have failed to document this finding
[10-14]. This study was conducted to determine the fre-
quency of hepatitis C in patients with LP at Razi hospital,
in Tehran, Iran.
Methods
In this case-control study 146 cases of LP were selected
using simple non-random (sequential) sampling. The
study was conducted during 1997 and 1998. Diagnosis of
LP was made by clinical observation and in suspicious
cases, diagnosis was confirmed by biopsy. Patients sus-
pected of drug-induced lichenoid eruptions, were not
included.
The demographic data such as age, gender, duration of ill-
ness and other pieces of information including type of
lesions, sites of involvement and patients' symptoms were
collected using a checklist after the patients' consent.
Hepatitis C antibody titer was measured by third genera-
tion Enzyme-Linked Immunosorbent Assay (Ortho® HCV
3.0 ELISA Test System; Ortho-Clinical Diagnostics, Rari-
tan, NJ, USA). We used the prevalence of HCV antibody
among 319375 volunteer blood donors (1996–1998) for
comparison as the control group [15]. Liver function tests
were also performed (Shimanzym-Iran).
Serum aspartate aminotransferase (AST) and alanine ami-
notransferase (ALT) levels ranging between 5 to 40 IU/lit,
alkaline phosphatase levels 70 to 306 IU/lit and bilirubin
concentrations below 1.4 mg/dl were assumed as normal.
The collected data were analyzed using SPSS (ver.10) soft-
ware. Mean age, duration of illness and laboratory tests
were compared between LP patients with and without
hepatitis C by using T-test. HCV antibody frequency was
compared in different groups using the chi-square test.
Results
Seven patients (4.8%) out of 146 had positive titer for
anti-HCV antibody. When compared to the control group
the odds ratio was 50.37(21.45–112.24). The clinical and
laboratory characteristics of these patients are detailed in
table 1.
The mean age of the patients in this study was 40.8 ± 15.7
years (patients were from ages 8–76). Sixty nine patients
(46.9%) were male and 78(53.1%) were female. Sites of
LP involvement were: skin in 137 patients (93.2%),
mucous membrane in 61 patients (41.5%), and nails in
28 patients (19.2%). Pruritus was seen in 124 patients
(90.5%).
The observed lesion types were as follows: nonerosive
mucosal in 57 patients (39%), hypertrophic in 45 patients
(30.6%), annular in 39 patients (26.5%), folicullar in 37
patients (25.2%), nonerosive palmoplantar in 29
patients(19.9%), nail lesions in 28 patients (19.2%),
atrophic in 14 patients (9.5%), erosive mucosal lesions in
11 patients (7.5%), guttate form in 14 patients (9.5%),
actinic in 7 patients (4.8%) and erosive palmoplantar
lesions in 1 patient (0.7%).
In 11 patients (7.5%) serum aspartate aminotransferase
(AST) levels were higher than normal and high levels of
alanine aminotransferase (ALT) were detected in 21
patients (14.3%). Higher levels of alkaline phosphatase
were observed in 7 (4.8%) patients. Five patients (3.4%)
had bilirubin concentrations higher than the normal
range.
Eight patients mentioned a history of blood transfusion, 4
in LP patients with HCV and 4 in those without HCV. The
history of transfusion was significantly higher in hepatitis
C group (P < 0.001).
Table 1: Clinical and laboratory characteristics of patients with LP and HCV
Patient No Sex/age LP clinical form Duration of LP Transaminase Levels History of transfusion
1 F /54 Hypertrophic/nail 6mo N +
2 F /25 Guttate/Annular/follicular 3y - +
3 M /15 Actinic/Erosive mucosal - High GPT(107) +
4 F /53 Nonerosive mucosal 3 mo High GPT(89) -
5 M /29 Erosive mucosal 5y N -
6 F /27 Hypertrophic/Erosive mucosal 6y High GPT(63) +
7 M /53 Hypertrophic 6y N -
F: female, M: male, mo: months, y: years, N: normal (5–40 IU/Lit)BMC Dermatology 2004, 4 http://www.biomedcentral.com/1471-5945/4/6
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Discussion
In recent years, both mucosal and cutaneous lichen pla-
nus have been reported to occur in the setting of chronic
HCV infection [14]. However, there are wide geographical
variations in the reported prevalence of HCV infection in
patients with LP, varying from 0% in England [16] to 63%
in Japan [17]. The available reports indicate that the prev-
alence of HCV antibodies in patients with mucosal and
cutaneous LP is significantly higher than that of the con-
trol populations (non-LP dermatologic patients or popu-
lation of blood donors) in Germany[8], Italy[18],
Spain[3,9], the USA and Japan,[14]suggesting an etiologic
role for HCV in LP. However studies in France [11,12] and
England [11,13,16] could not demonstrate a statistically
significant association between HCV and LP. Erkek et al
[14] found that HCV antibody prevalence in Turkish
patients with LP (12.9%) was higher than that of the con-
trol group (3.7%) but the difference was not statistically
significant, whereas Kirtek et al [7] found statistically sig-
nificant difference in Gaziantep region of Turkey.
According to our study HCV antibody prevalence in Ira-
nian patients with LP was 4.8%. It was significantly higher
than anti-HCV antibody prevalence in blood donors
(0.1%), used as control group (P < 0.001). To our knowl-
edge, there is no previous study evaluating the prevalence
of anti-HCV in Iranian LP patients.
In our cases GOT was higher than the normal range in
11(7.5%) patients, none of them were HCV infected. A
high level of alkaline phosphatase was measured in 14
(9.5%) patients. The bilirubin concentration was abnor-
mal in 7% of cases. There was no significant difference in
liver function tests between HCV infected and non
infected groups.
As expected, there were significantly more cases with pos-
itive transfusion history among hepatitis C affected group
(P < 0.001).
Type of LP and lesional location did not differ between
the two groups. As with other studies [3,9,18], mucosal
erosions were more common in hepatitis C patients (p <
0.001).
The pathogenic role of HCV in the development of LP is
still unclear. For some authors the association of LP and
positive serology for HCV, even positive RNA is not a sub-
stantive enough reason to determine the role of HCV in
the pathogenesis of LP. Nevertheless, demonstration of
HCV RNA in epithelial cells of oral mucosa [19,20] and
skin lesions [14] of patients with LP would lead to the the-
ory that direct action of the virus is involved. HCV could
be a potential antigen presented by Langerhans cells, fol-
lowed by activation and migration of lymphocytes result-
ing in damage to basal cells via cytockines of cytotoxic T
cells [21,18]. The virus may alter epithelial antigenicity at
sites of mucocutaneous replication leading either to direct
activation of cytotoxic T cells [13,21] or to production of
antibodies against epithelial antigens [23]. Recently,
Petruzzi et al [24] demonstrated differences in lym-
phocyte subpopulations between HCV positive oral LP
patients and HCV negative patients with oral LP. They
attributed this to the chronic antigenic stimulation of
HCV. On the other hand, the different results in previous
studies and the differences in respect to the geographic
area could be in relation to the different genetic suscepti-
bility of the hosts. Carrozzo et al [25] have suggested that
genetic polymorphism of interferon-gamma and tumor
necrosis factor-alpha may contribute to the development
of oral and orocutaneous involvement, respectively.
Conclusions
It seems that screening for anti-HCV antibody is valuable
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